Evidence map›Paper›PMID 34377493›Full record

ArticleRespirology case reports2021

Dramatic response to alectinib in an

Kazuki Masuda, Masafumi Saiki, So Shimamura, Shuichiro Ide, Yoshinori Uchida, Yusuke Sogami, Hiroshi Ishihara, Fumi Ikeda, Kiyotaka Kugiyama

Open access · goldAbstract readCase Reports
In one paragraph

Article in Respirology case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. A favorable antitumor efficacy of sotorasib in a patient withInternational cancer conference journal · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Dramatic response to alectinib in anRespirology case reports · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kazuki MasudaDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Masafumi SaikiDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
So ShimamuraDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Shuichiro IdeDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Yoshinori UchidaDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Yusuke SogamiDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Hiroshi IshiharaDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
Fumi IkedaDepartment of Internal Medicine Nirasaki City Hospital Nirasaki Japan.
Kiyotaka KugiyamaDepartment of Internal Medicine II University of Yamanashi, Faculty of Medicine Chuo Japan.
University of Yamanashi Hospital · JPUniversity of Yamanashi · JPKomaki City Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The echinoderm microtubule-associated protein-like 4 (

Indexed as

alectinibechinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinaselarge cell neuroendocrine carcinomapoor performance status

Identifiers

PMID34377493
PMCPMC8333770
OpenAlexW3190256566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.